Health Catalyst Posts $40.5M Q3 Net Income
HCAT sits 57% above its 52-week low of $0.955.
Summary
Health Catalyst reported $40.5 million of third-quarter net income, or 53 cents a share, a swing to profit for a company that posted a $151.6 million net loss in Q2 2026, which included a $122.5 million goodwill impairment. Third-quarter revenue was $56.3 million, and the results came in above guidance, with the company reaffirming its 2026 outlook. Adjusted EBITDA declined sharply on the Vitalware divestiture. The result lands as new CEO Simeon Kohl, in the seat since September 14, works under pressure from activist Palogic Value Management, which holds 7.1% and has demanded a clear business plan. A profitable quarter is the strongest answer management could give to that critique.
At the time of this announcement, HCAT was trading at $1.50 on NASDAQ in the Technology sector, with a market capitalization of approximately $112.9M. The 52-week trading range was $0.96 to $3.36. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.